ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 206 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2020. The put-call ratio across all filers is 0.50 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $677,849 | -25.1% | 19,014 | -3.1% | 0.00% | -50.0% |
| Q2 2023 | $904,748 | +51.6% | 19,613 | +31.7% | 0.00% | +100.0% |
| Q1 2023 | $596,969 | -9.5% | 14,887 | +4.6% | 0.00% | 0.0% |
| Q4 2022 | $659,368 | +38.2% | 14,232 | +23.5% | 0.00% | 0.0% |
| Q3 2022 | $477,000 | +4.6% | 11,522 | +50.8% | 0.00% | 0.0% |
| Q2 2022 | $456,000 | -18.4% | 7,639 | -0.8% | 0.00% | 0.0% |
| Q1 2022 | $559,000 | +4.1% | 7,704 | +20.6% | 0.00% | 0.0% |
| Q4 2021 | $537,000 | -6.6% | 6,386 | +0.1% | 0.00% | 0.0% |
| Q3 2021 | $575,000 | -2.5% | 6,379 | +3.2% | 0.00% | 0.0% |
| Q2 2021 | $590,000 | -20.4% | 6,184 | -5.0% | 0.00% | 0.0% |
| Q1 2021 | $741,000 | -12.4% | 6,507 | +6.4% | 0.00% | -50.0% |
| Q4 2020 | $846,000 | +95.8% | 6,116 | +16.4% | 0.00% | +100.0% |
| Q3 2020 | $432,000 | +20.0% | 5,253 | +14.2% | 0.00% | 0.0% |
| Q2 2020 | $360,000 | – | 4,599 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| First Light Asset Management, LLC | 213,887 | $29,608,000 | 2.19% |
| Rock Springs Capital Management LP | 566,500 | $78,421,000 | 1.66% |
| FEDERATED HERMES, INC. | 4,280,528 | $592,554,000 | 1.21% |
| AtonRa Partners | 17,646 | $2,443,000 | 1.20% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 218,390 | $30,232,000 | 1.05% |
| EMERALD ADVISERS, LLC | 226,875 | $31,406,000 | 1.04% |
| Atika Capital Management LLC | 89,000 | $12,319,000 | 0.96% |
| Capital Impact Advisors, LLC | 25,582 | $3,541,000 | 0.87% |
| JGP Global Gestao de Recursos Ltda. | 1,586 | $220,000 | 0.83% |
| CAPITAL INTERNATIONAL LTD /CA/ | 79,742 | $11,039,000 | 0.64% |